BiotechTube
Home/Kyverna Therapeutics/Beth Seidenberg, MD
BS

Beth Seidenberg, MD

Director

Kyverna Therapeutics

Roles

DirectoratKyverna Therapeutics
Lead Independent DirectoratSagimet Biosciences

Therapeutic Areas

Autoimmune DiseasesImmunology

Kyverna Therapeutics Pipeline

DrugIndicationPhase
KYV-101Lupus Nephritis (Systemic Lupus Erythematosus)Phase 1/2
KYV-201Undisclosed autoimmune indicationPreclinical

Leadership Team at Kyverna Therapeutics

PM
Peter Maag, PhD
Chief Executive Officer
DR
Dominik Rüttinger, MD, MSc
Chief Medical Officer
JV
Jens Vogel, PhD
Chief Scientific Officer
KM
Keith Maher, JD
Chief Business Officer
SS
Simona Skerjanec, PharmD, MBA
Chief Operating Officer
TL
Timothy Lu, MD, MBA
Chief Financial Officer
TS
Timothy Springer, PhD
Chair of the Board of Directors
LE
Luke Evnin, PhD
Director
CD
Cameron Durrant, MD, MBA
Director
View full Kyverna Therapeutics profile